Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate Safety and Preliminary Efficacy of TISA-818-Inj in Patients With Acute Respiratory Distress Syndrome
NCT07319351 is registered in ClinicalTrials.gov with EnliTISA (Shanghai) Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate Safety and Preliminary Efficacy of TISA-818-Inj in Patients With Acute Respiratory Distress Syndrome
- Lead sponsor
- EnliTISA (Shanghai) Pharmaceutical Co., Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 12, 2023
- Completion date
- September 15, 2025
- Enrollment
- 57 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute respiratory distress syndrome (ards)